27 patents
Utility
Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
19 Dec 23
The present disclosure relates to oral compositions of Compound I or a derivative thereof.
Walter Smith, Joseph Monahan, Edward Hellriegel, David Gordon, Heidi Hope, John Robert Springer, Gary A. Decrescenzo
Filed: 26 Mar 21
Utility
Pyrrolopyrimidine ITK inhibitors
21 Nov 23
Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Susan Landis Hockerman, Richard Heier, Paramita Mukherjee
Filed: 21 Apr 21
Utility
Crystalline Polymorph Form a of a Jak Inhibitorand Methods for Its Preparation
16 Nov 23
The present application relates to a novel crystalline form of ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3 -b]pyridine-5-carboxylate (Compound 1).
Gary DECRESCENZO, John R. SPRINGER, Jon P, LAWSON
Filed: 24 Sep 21
Utility
Methods of synthesizing substituted pyridinone-pyridinyl compounds
26 Sep 23
The present disclosure provides methods of synthesizing a compound of Formula (P)-I.
Gary A. Decrescenzo, John Robert Springer
Filed: 23 Nov 21
Utility
Methods of Synthesizing Deuterated Substituted Pyridinone-pyridinyl Compounds
14 Sep 23
The present disclosure provides methods of synthesizing a compound of Formula (P)-I and a compound of Formula (P)-II.
Gary A. DECRESCENZO, John Robert SPRINGER, Jon P. LAWSON
Filed: 3 Feb 23
Utility
Process, Compositions, and Crystalline Forms of Substituted Pyridinone-pyridinyl Compounds
3 Aug 23
The present disclosure provides a crystalline form of the methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compound of the structure: XRPD, TGA, and DSC data on the crystalline form, as well as methods preparing the crystalline form, including a multi-kilo scale preparation.
Gary A. DECRESCENZO, John Robert SPRINGER, Susan Landis HOCKERMAN
Filed: 26 Mar 21
Utility
CorrectedMethods of Synthesizing Substituted Pyridinone-pyridinyl Compounds
29 Jun 23
The present disclosure provides methods of synthesizing a compound of Formula (P)-I.
Gary A. DECRESCENZO, John Robert SPRINGER
Filed: 23 Nov 21
Utility
Methods and Compositionsfor Treating Viral Infections
18 May 23
Compositions and methods that may be useful for the treatment of a viral infection as well as for treating infection induced cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) are described herein.
Paul CHANGELIAN, Joseph MONAHAN, David GORDON, Neal Stuart WALKER, Walter SMITH
Filed: 26 Mar 21
Utility
Substituted Pyrrolopyridines As Jak Inhibitors
24 Nov 22
Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Paramita MUKHERJEE, Paul CHANGELIAN, Canxin XU
Filed: 30 Jun 22
Utility
Pyrrolopyrimidine Itk Inhibitors
3 Nov 22
Eric Jon JACOBSEN, David Randolph ANDERSON, James Robert BLINN, Susan Landis HOCKERMAN, Richard HEIER, Paramita MUKHERJEE
Filed: 21 Apr 21
Utility
Deuterated MK2 Pathway Inhibitors and Methods of Using the Same
15 Sep 22
David Randolph ANDERSON, Gary Anthony DECRESCENZO
Filed: 31 Jul 20
Utility
Substituted pyrrolopyridines as JAK inhibitors
23 Aug 22
Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Paramita Mukherjee, Paul Changelian, Canxin Xu
Filed: 4 May 20
Utility
Methods of Synthesizing Substituted Pyridinone-pyridinyl Compounds
28 Jul 22
The present disclosure provides methods of synthesizing a compound of Formula (P)-I.
Gary A. DECRESCENZO, John Robert SPRINGER
Filed: 23 Nov 21
Utility
Substituted Sulfonamide Pyrrolopyridines As Jak Inhibitors
28 Jul 22
David Randolph ANDERSON, Eric Jon JACOBSEN, James Robert BLINN, Susan Landis HOCKERMAN, Paramita MUKHERJEE, Paul CHANGELIAN
Filed: 31 Jul 20
Utility
Oral Compositions of MK2 Pathway Inhibitor for Treatment of Immune Conditions
4 Nov 21
The present disclosure relates to oral compositions of Compound I or a derivative thereof.
Walter SMITH, Joseph MONAHAN, Edward HELLRIEGEL, David GORDON, Heidi HOPE, John Robert SPRINGER, Gary A. DECRESCENZO
Filed: 26 Mar 21
Utility
Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same
16 Sep 21
The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease.
David Randolph ANDERSON, Susan Landis HOCKERMAN, James Robert BLINN, Eric Jon JACOBSEN
Filed: 16 Mar 21
Utility
Pyrrolopyrimidine ITK inhibitors
1 Jun 21
Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Susan Landis Hockerman, Richard Heier, Paramita Mukherjee
Filed: 12 Aug 19
Utility
Peroxide Formulations and Methods and Applicators for Using the Same
13 May 21
Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions.
Stuart D. SHANLER, Christopher POWALA, Christopher PHILLIPS, Brian BEGER, Charles Rodney GREENAWAY-EVANS, Sian Tiong LIM, Marc Barry BROWN, Michael A. BOTTA, Thomas NAGLER
Filed: 23 Jun 20
Utility
Substituted Pyrrolopyridines As Jak Inhibitors
4 Nov 20
Eric Jon Jacobsen, David Randolph Anderson, James Robert Blinn, Paramita Mukherjee, Paul Changelian, Canxin Xu
Filed: 3 May 20
Utility
Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
12 Oct 20
The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease.
David Randolph Anderson, Susan Landis Hockerman, James Robert Blinn, Eric Jon Jacobsen
Filed: 1 Nov 18